Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Useful Bacteria Need Protection

04.07.2005


New forms of drugs for dysbacteriosis and other gastrointestinal disturbances are being developed by the Novosibirsk researchers with support of the International Science and Technology Center (ISTC).



A lot of Russians suffer from malfunction of gastrointestinal tract. The frequent reason for that is dysbacteriosis – disturbances of normal intestinal flora. To fight dysbacteriosis, physicians prescribe eubiotic drugs to patients, which contain bacteria necessary for digestion, for example, bifidumbacterin, lactobacterin, colibacterin, bificol, etc. The drugs are good, but upon intake they are destroyed in the stomach, due to that their efficiency reduces. To increase efficiency of eubiotics, they should be protected in some way.

This problem is being solved by the researchers of the State Research Center for Virology and Biotechnology “Vector” (“Vector-BiAlgam” close corporation (Koltsovo, Novosibirsk Region)) with support of the International Science and Technology Center (ISTC). Bacteria making part of the drugs need protection, and there are two main methods to defend them. The bacteria are either placed into a capsule – this is a capsulated form of drug, or they are placed on a special carrier - sorbent – this is an immobilized form.


The Novosibirsk researchers are developing and testing immobilized eubiotics. In this medication, cells of useful bacteria are placed on porous microcarrier SUMS-1 – aluminium oxide powder, the size of microparticles varying from 40 to 100 mkm, the surface of microparticles being covered by carbon (which is used in medicine as enterosorbent). Adsorption occurs on the carrier owing to both physical and chemical mechanisms. Proteins of the cellular wall of bacteria form chelates with the SUMS-1 surface, where magnesium serves as a complexing agent (chelation). In this case, active groups of bacteria’s proteins and lipoproteids turn out to be protected from the stomach’s aggressive acid medium. In the meantime, unprotected bifido- and lactobacteria lose more than 90 percent of their activity in the stomach, the immobilized ones go lossless through the stomach.

Chelates are known for their stability being dependent on the medium. As the stomach has acid medium, bacteria remains in it bound with sorbent. When the drug gets into lower parts of thin bowels, the chelate disintegrates due to increased. This is what is needed, because it is particularly in the thin bowels and than in the thick bowels that bifido- and lactobacteria get released from the carrier and start working. The released sorbent surface takes away toxins and metabolic products. SUMS-1 is a very efficient enterosorbent: it does not sorb small molecules - acids, carbohydrates, trace elements and it does not sorb large mass proteins either – transport proteins and enzymes. That is why the water-salt balance is not broken and bowel’ enzymatic activity does not decrease. Along with that, SUMS-1 actively binds proteins of medium mass, where toxins and products of uncomplete metabolism belong to. They are brought out of the organism together with the sorbent.

The Novosibirsk researchers have created complex eubiotic based on the SUMS-1sorbent, which includes consortium of several species of the most active cultures of bifido- and lactobacteria. These bacteria suppress reproduction of pathogenic, saprogenous and gas-producing microflora, they participate in peptic processes and synthesis of vitamins, in metabolism of trace elements and biologically active substances. On top of that, bifido- and lactobacteria act as immunostimulants.

New drugs underwent investigation at all levels. Testing them on laboratory animals, the researchers have made sure that they are non-toxic, do not cause side effects and at the same time destroy harmful intestinal flora and increase vital capacity of the organism. While clinical trials of the complex immobilized eubiotic are being prepared, the Novosibirsk State Medical Academy (based on the clinic) has already carried out clinical trials of its analogue called “Ecoflor”, which belongs to the category of bioactive nutritional supplements. 70 patients who were taking “Ecoflor” within two weeks have improved digestion and general habitus, and the gut organisms have become normal. The complex eubiotic production is still limited to pilot batches, and its analogue “Ecoflor” is already produced as a bioactive nutritional supplement.

And finally, it should be pointed out where new eubiotic drugs will be applied. They will be used not only for dysbacteriosis but also for toxin poisoning, enteric infection, pancreatitis, gastritis, ulcer and other chronic ailments, allergy, radiolesion and even tuberculosis and oncology treatment.

Sergey Komarov | alfa
Further information:
http://www.informnauka.ru

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>